- Home
- BKV vs VCEL Comparison
BKV vs VCEL Comparison
Compare BKV & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BKV | VCEL |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 2022 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BKV | VCEL |
|---|---|---|
| Price | $25.12 | $40.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $34.22 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 909.9K | 449.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 199.00 | 60.00 |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $893,781,000.00 | $276,259,000.00 |
| Revenue This Year | $69.39 | $19.40 |
| Revenue Next Year | $9.45 | $18.24 |
| P/E Ratio | $22.63 | ★ N/A |
| Revenue Growth | ★ 47.85 | 16.45 |
| 52 Week Low | $20.08 | $28.95 |
| 52 Week High | $32.81 | $49.32 |
Technical Indicators
Market Signals| Indicator | BKV | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 38.48 |
| Support Level | $25.03 | $35.45 |
| Resistance Level | $27.59 | $42.16 |
| Average True Range (ATR) | 0.95 | 1.39 |
| MACD | -0.02 | -0.33 |
| Stochastic Oscillator | 46.24 | 23.24 |
Price Performance
Historical ComparisonAbout BKV BKV Corporation
BKV Corp is a growth-driven energy company focused on the development of natural gas-producing assets, the ownership and operation of natural gas-fired power generation assets, and selective accretive acquisitions. The company's core businesses are the production of natural gas and the generation of natural gas-fired power from its owned and operated assets, supported by a closed-loop plan, enabled by its upstream, midstream, power, and CCUS businesses.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.